Condition: Hyperkalaemia · Chronic Kidney Disease Stage 3 and 4 · Dietary Intervention · Sponsor: Mario Negri Institute for Pharmacological Research
This is a phase III, prospective, randomized, double-blind, placebo-controlled, single-center, pilot trial, aimed at assessing whether treatment with the oral potassium binder patiromer as compared to placebo allows withdrawal or down-titration of potassium dietary restriction without increasing the risk of hyperkalemia in chronic dialysis patients.
This description comes directly from the study's public registry record.
Piero L Ruggenenti, M.D. · +390352673814 · pruggenenti@asst-pg23.it
Always discuss trial participation with your own doctor first.
| Nephrology Unit, ASST Papa Giovanni XXIII | Bergamo, BG, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06858280